We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-0.8%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$210M
AUM Growth
+$27M
(+15%)
Cap. Flow
+$34.5M
Cap. Flow
% of AUM
16.43%
Top 10 Holdings %
Top 10 Hldgs %
68.42%
Holding
39
New
7
Increased
15
Reduced
3
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dentsply Sirona
XRAY
|
+$13.8M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
+$9.65M |
| 3 |
SRCL
Stericycle Inc
SRCL
|
+$9.37M |
| 4 |
NUVA
NuVasive, Inc.
NUVA
|
+$7.59M |
| 5 |
VSI
Vitamin Shoppe Inc.
VSI
|
+$4.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pacira BioSciences
PCRX
|
+$6.99M |
| 2 |
Nektar Therapeutics
NKTR
|
+$6.27M |
| 3 |
Labcorp
LH
|
+$5.64M |
| 4 |
Quest Diagnostics
DGX
|
+$4.92M |
| 5 |
QuidelOrtho
QDEL
|
+$4.89M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.81% |
| 2 | Industrials | 5.57% |
| 3 | Consumer Discretionary | 2.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OPTN
26
DELISTED
OptiNose
OPTN
| $1.65M | 0.78% |
+5,488
| New | +$1.52M |
|
|
HIND
27
Vyome Holdings
HIND
$13.9M
| – | – |
0
| – | – |
|
28
PUT
Boston Scientific
BSX
$69B
| – | – |
-1,500
| Closed | -$328K |
|
|
29
Quest Diagnostics
DGX
$26B
| – | – |
-50,000
| Closed | -$4.92M |
|
30
CALL
HCA Healthcare
HCA
$90.2B
| – | – |
-1,000
| Closed | -$845K |
|
31
PUT
iShares Russell 2000 ETF
IWM
$80.4B
| – | – |
-2,000
| Closed | -$96K |
|
32
McKesson
MCK
$103B
| – | – |
-25,000
| Closed | -$3.9M |
|
|
33
Nektar Therapeutics
NKTR
$2.35B
| – | – |
-7,000
| Closed | -$6.27M |
|
34
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
| – | – |
-4,000
| Closed | -$168K |
|
35
PUT
Thermo Fisher Scientific
TMO
$214B
| – | – |
-100
| Closed | -$54K |
|
36
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.1B
| – | – |
-2,000
| Closed | -$230K |
|
|
RCM
37
DELISTED
R1 RCM Inc. Common Stock
RCM
| – | – |
-400,000
| Closed | -$1.76M |
|
|
ADMS
38
DELISTED
Adamas Pharmaceuticals
ADMS
| – | – |
-92,600
| Closed | -$3.14M |
|
|
SHPG
39
CALL
DELISTED
Shire pic
SHPG
| – | – |
-394
| Closed | -$5K |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q1 2018 Portfolio in Review
As of Q1 2018, Tamarack Advisers held 39 positions worth $210M, up 15% from $183M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Tamarack Advisers deployed $34.5M of net new capital in Q1 2018, opening 7 new positions and adding to 15 existing holdings. Its largest new stake was Dentsply Sirona: 235,000 shares worth $11.8M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 92% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Pacira BioSciences, an estimated $6.99M trimmed.
- Tamarack Advisers's largest Q1 2018 buy was Dentsply Sirona: 235,000 shares worth $11.8M.
- Tamarack Advisers added most to Stericycle Inc in Q1 2018, an estimated $9.37M increase.
- Tamarack Advisers's biggest Q1 2018 reduction was Pacira BioSciences, cutting an estimated $6.99M.
- Tamarack Advisers fully exited Nektar Therapeutics in Q1 2018, selling an estimated $6.27M.
- Tamarack Advisers's ten largest holdings make up 68% of its $210M portfolio in Q1 2018.
- Tamarack Advisers opened 7 new positions and closed 12 in Q1 2018.
- Tamarack Advisers's portfolio value rose 15% quarter-over-quarter to $210M.
Based on Tamarack Advisers's 13F filing for Q1 2018, filed 8 May 2018.